DHG Pharmaceutical JSC (STC:DHG) Piotroski F-Score: 6 (As of Aug. 09, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:DHG DHG Pharmaceutical JSC STC:DHG
94 GF Score
Price ₫95,600.00
GF Value ₫113,364.13
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is DHG Pharmaceutical JSC Piotroski F-Score?

DHG Pharmaceutical JSC STC:DHG +0.84% 94 Piotroski F-Score is 6 as of Aug. 09, 2026, which is at its 10-year median of 6.00. GuruFocus rates STC:DHG with a GF Score™ of 94/100 and a GF Value™ of ₫113,364.13 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 977 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 78.71% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DHG Pharmaceutical JSC has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for DHG Pharmaceutical JSC's Piotroski F-Score or its related term are showing as below:

STC:DHG' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of DHG Pharmaceutical JSC was 9. The lowest was 3. And the median was 6.

DHG Pharmaceutical JSC  (STC:DHG) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


DHG Pharmaceutical JSC Piotroski F-Score Related Terms


DHG Pharmaceutical JSC Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for DHG Pharmaceutical JSC's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DHG Pharmaceutical JSC Piotroski F-Score Chart

DHG Pharmaceutical JSC Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 8.00 3.00 4.00 8.00

DHG Pharmaceutical JSC Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 8.00 8.00 8.00 6.00

STC:DHG vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DHG Pharmaceutical JSC Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where DHG Pharmaceutical JSC's Piotroski F-Score falls into.


STC:DHG
94GF Score
DHG Pharmaceutical JSC STC:DHG
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 209644.276 + 184797.127 + 315677.281 + 298667.559 = ₫1,008,786 Mil.
Cash Flow from Operations was 56677.854 + 436429.442 + 5959.732 + 214231.943 = ₫713,299 Mil.
Revenue was 1145709.088 + 1742471.806 + 1198100.183 + 1363150.472 = ₫5,449,432 Mil.
Gross Profit was 561669.299 + 798089.923 + 600227.549 + 707799.829 = ₫2,667,787 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(5495044.458 + 5600956.966 + 5173881.629 + 5245728.16 + 5005487.53) / 5 = ₫5304219.7486 Mil.
Total Assets at the begining of this year (Jun25) was ₫5,495,044 Mil.
Long-Term Debt & Capital Lease Obligation was ₫0 Mil.
Total Current Assets was ₫3,744,553 Mil.
Total Current Liabilities was ₫1,514,292 Mil.
Net Income was 156014.719 + 208192.211 + 266239.849 + 236894.865 = ₫867,342 Mil.

Revenue was 1061838.685 + 1458678.268 + 1194544.777 + 1184237.014 = ₫4,899,299 Mil.
Gross Profit was 461251.784 + 666396.135 + 567386.132 + 585226.355 = ₫2,280,260 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(6155169.131 + 6253272.867 + 5959243.276 + 5755508.307 + 5495044.458) / 5 = ₫5923647.6078 Mil.
Total Assets at the begining of last year (Jun24) was ₫6,155,169 Mil.
Long-Term Debt & Capital Lease Obligation was ₫0 Mil.
Total Current Assets was ₫4,165,086 Mil.
Total Current Liabilities was ₫1,631,777 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DHG Pharmaceutical JSC's current Net Income (TTM) was 1,008,786. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DHG Pharmaceutical JSC's current Cash Flow from Operations (TTM) was 713,299. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=1008786.243/5495044.458
=0.18358109

ROA (Last Year)=Net Income/Total Assets (Jun24)
=867341.644/6155169.131
=0.14091272

DHG Pharmaceutical JSC's return on assets of this year was 0.18358109. DHG Pharmaceutical JSC's return on assets of last year was 0.14091272. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

DHG Pharmaceutical JSC's current Net Income (TTM) was 1,008,786. DHG Pharmaceutical JSC's current Cash Flow from Operations (TTM) was 713,299. ==> 713,299 <= 1,008,786 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=0/5304219.7486
=0

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=0/5923647.6078
=0

DHG Pharmaceutical JSC's gearing of this year was 0. DHG Pharmaceutical JSC's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=3744552.782/1514291.941
=2.47280771

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=4165085.715/1631776.602
=2.55248525

DHG Pharmaceutical JSC's current ratio of this year was 2.47280771. DHG Pharmaceutical JSC's current ratio of last year was 2.55248525. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

DHG Pharmaceutical JSC's number of shares in issue this year was 134.778. DHG Pharmaceutical JSC's number of shares in issue last year was 134.752. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2667786.6/5449431.549
=0.48955319

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2280260.406/4899298.744
=0.46542588

DHG Pharmaceutical JSC's gross margin of this year was 0.48955319. DHG Pharmaceutical JSC's gross margin of last year was 0.46542588. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=5449431.549/5495044.458
=0.99169926

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=4899298.744/6155169.131
=0.79596493

DHG Pharmaceutical JSC's asset turnover of this year was 0.99169926. DHG Pharmaceutical JSC's asset turnover of last year was 0.79596493. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+0+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DHG Pharmaceutical JSC has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
DHG Pharmaceutical JSC (STC:DHG) has a Piotroski F-Score of 6 as of Aug. 09, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on DHG Pharmaceutical JSC and its competitors. This is near median its historical median of 6.00. Over the past decade, DHG Pharmaceutical JSC's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #208 out of 977 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is DHG Pharmaceutical JSC's Piotroski F-Score too high?
DHG Pharmaceutical JSC's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. DHG Pharmaceutical JSC's value of 6 is 20% above this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #208 out of 977 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DHG Pharmaceutical JSC has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #208 out of 977 companies for Piotroski F-Score. This places DHG Pharmaceutical JSC in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. DHG Pharmaceutical JSC's value of 6 is 20% above this benchmark. Historically, DHG Pharmaceutical JSC's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, DHG Pharmaceutical JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,364.13, compared to a current price of ₫95,600.00 — trading 15.7% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Drug Manufacturers industry median of 5.00. DHG Pharmaceutical JSC's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current Piotroski F-Score is 6 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?

Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued. The current stock price of ₫95,600.00 is trading 15.7% below its estimated GF Value™ of ₫113,364.13. GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.

Key valuation signals for STC:DHG:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: ₫113,364.13 vs. price of ₫95,600.00 (15.7% below fair value)
  • GF Score™: 94/100 with 4 warning signs
  • Industry Position: 20% above the Drug Manufacturers median (#208 of 977)

No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DHG Pharmaceutical JSC Business Description

Address 288 Bis Nguyen Van Cu, An Hoa Ward, Ninh Kieu District, Can Tho, VNM
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
94GF Score

Get the complete analysis for STC:DHG

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫95,600.00
Price
₫113,364.13
GF Value